NCT01814800已完成3 期
An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 59
- 试验地点
- 9
- 主要终点
- Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))
研究概览
简要总结
This is a Phase III, multicenter, open-label study of RI-002 administered as an intravenous infusion of RI-002 (IGIV) every 21 or 28 days in approximately 60 subjects with Primary Immunodeficiency Diseases (PIDD).
详细描述
Primary immunodeficiency diseases (PIDDs) are genetically determined disorders of the immune system resulting in greatly enhanced susceptibility to infectious disease, autoimmunity and malignancy. As most subjects with PIDDs present with infections, the differential diagnosis and initial investigations for an underlying immune defect are typically guided by the clinical presentation. In subjects with PIDDs, individual infections are not necessarily more severe than those that occur in a normal host. Rather, the clinical features suggestive of an immune defect may be the recurring and/or chronic nature of infections with common pathogens that may result in end organ damage, such as bronchiectasis. Several immune globulin products have already been approved by the FDA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 75 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •To be eligible to participate in this study, the subjects must meet the following criteria:
- •Signed a written informed consent or a specific assent form for minors.
- •Have a diagnosis of primary immunodeficiency disease.
- •Be ≥ 2 years and ≤ 75 years.
- •Have body weight ≥ 12 kg at screening.
- •Have been receiving IGIV at a dose that has not been changed by >50% of the mean dose on a mg/kg basis for at least 3 months prior to study entry and have maintained a trough serum Immunoglobulin G (IgG) level ≥ 500 mg/dL on the previous 2 assessments prior to receiving RI
- •The trough level must be at least 300 mg/dL above the pre-treatment serum IgG level.
- •For female subjects, be of non-childbearing potential or have a negative pregnancy test prior to study start and be deemed not at risk of becoming pregnant by adherence to a reliable contraceptive method for the duration of the study.
排除标准
- •Subjects must be excluded if they meet any of the following criteria:
- •Have a known hypersensitivity to immunoglobulin or any excipient in RI-
- •Have a history of a severe anaphylactic or anaphylactoid reaction to blood or any blood-derived product.
- •Have a specific Immunoglobulin A (IgA) deficiency, history of allergic reaction to products containing IgA or has demonstrable antibodies to IgA.
- •Have uncompensated hemodynamically significant congenital or other heart disease.
- •Have a medical condition that is known to cause secondary immune deficiency.
- •Have a significant T-cell deficiency or deficiency of granulocyte number or function.
- •Have significant renal impairment or have a history of acute renal failure.
- •Have abnormal liver function.
- •Be receiving chronic anti-coagulation therapy.
- •Have a history of deep vein thrombosis (DVT), thrombotic or thrombo-embolic event, or are at increased risk for thrombotic events.
- •Current daily use of the following medications:
- •corticosteroids (> 7.5 mg (or equivalent dose on a mg/kg basis) of prednisone equivalent per day for > 30 days)
- •immunomodulatory drugs
- •immunosuppressive drugs (excluding topical pimecrolimus (Elidel) and tacrolimus (Protopic))
- •Administration of a hyperimmune or specialty high titer immunoglobulin product.
- •Have uncontrollable arterial hypertension.
- •Have a history of hemolysis or positive Coombs test while undergoing treatment with IGIV therapy.
- •Be morbidly obese as indicated by a Body Mass Index (BMI) ≥ 40
- •Have received any blood product (other than Immunoglobulin G) within 3 months prior to screening.
- •Have received any Respiratory Syncytial Virus (RSV) specific products, including palivizumab (Synagis®) within 3 months prior to screening.
- •Have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs within the past 12 months.
- •Have any condition or abnormal laboratory assessment judged by the investigator to preclude participation in the study.
- •Are currently pregnant or nursing.
- •Have hepatitis A, B, or C.
研究组 & 干预措施
RI-002 Treatment
Experimental
Drug: RI-002 Dose: 300-800 mg/kg infusion Frequency: Once every 3 to 4 Weeks
干预措施: RI-002 (Biological)
结局指标
主要结局
Number of Serious Bacterial Infections (SBIs) Per Subject Per Year (FDA Guidance for Industry (2008))
时间窗: One year
The primary objective of this study was to demonstrate that RI-002 (IGIV) reduces the frequency of serious bacterial infections (SBIs), as defined by the Diagnostic Criteria for Serious Infection Types guideline, in subjects with primary humoral immunodeficiency.
次要结局
- Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Combined Days Lost(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Haemophilus Influenzae Type B(Up to 1 year)
- Number of Days Lost From Work/School/Daycare and Usual Activities Due to Infections and Their Treatment - Per Subject-Year(Up to 1 year)
- Number of Unscheduled Visits to Physician/ER Due to Infections - Total Number of Visits(Up to 1 year)
- Time to Resolution of Infections - Infection Days Per Subject(Up to 1 year)
- Days of Hospitalization Due to Infections(Up to 1 year)
- Days of Hospitalization Due to Infections - Per Subject-Year(Up to 1 year)
- Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection)(Up to 1 year)
- Number of Days of Antibiotic Therapy (Prophylaxis and Treatment of Infection) - Per Subject-Year(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 9V(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 14(Up to 1 year)
- Incidence of All Infections (Serious and Non-serious)(Up to 1 Year)
- Number of Unscheduled Visits to Physician/ER Due to Infections - Per Subject-Year(Up to 1 year)
- Number of Hospitalizations Due to Infections(Up to 1 year)
- Number of Hospitalizations Due to Infections - Per Subject-Year(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Tetanus(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 3(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 5(Up to 1 year)
- Time to Resolution of Infections - Duration Per Infection(Up to 1 year)
- Correlation Between Trough Level of RI-002 and Serious and Non-serious Infections(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - IgG(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 7F(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19A(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Respiratory Syncytial Virus (RSV)(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 4(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 18C(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 23F(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 1(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 6B(Up to 1 year)
- Trough Total IgG and Specific Antibody Levels - Streptococcus Pneumoniae, Serotype 19F(Up to 1 year)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
2 期
Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer PatientsBreast Cancer MetastaticNCT03328884MedSIR55
已完成
3 期
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508delCystic FibrosisNCT02797132Vertex Pharmaceuticals Incorporated62
招募中
1 期
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLCNon-small Cell Lung Cancer (NSCLC)NCT06754930Suzhou Suncadia Biopharmaceuticals Co., Ltd.400
招募中
1 期
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsLocally Advanced Unresectable or Metastatic Solid TumorsNCT05636215Innovent Biologics (Suzhou) Co. Ltd.368
终止
2 期
An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain MetastasisBrain MetastasesNCT03911869Pfizer13